Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

The structural basis of agonist-induced activation in constitutively active rhodopsin.

Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, Schertler GF.

Nature. 2011 Mar 31;471(7340):656-60. doi: 10.1038/nature09795. Epub 2011 Mar 9.

2.

Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.

Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJ, Moore JP.

Virology. 2011 Apr 25;413(1):47-59. doi: 10.1016/j.virol.2010.12.052. Epub 2011 Feb 26.

3.

New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.

Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, Arenzana-Seisdedos F, Lagane B.

J Biol Chem. 2011 Feb 18;286(7):4978-90. doi: 10.1074/jbc.M110.168955. Epub 2010 Nov 30.

4.
5.

Tracking G-protein-coupled receptor activation using genetically encoded infrared probes.

Ye S, Zaitseva E, Caltabiano G, Schertler GF, Sakmar TP, Deupi X, Vogel R.

Nature. 2010 Apr 29;464(7293):1386-9. doi: 10.1038/nature08948. Epub 2010 Apr 11.

PMID:
20383122
6.

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.

Ogert RA, Hou Y, Ba L, Wojcik L, Qiu P, Murgolo N, Duca J, Dunkle LM, Ralston R, Howe JA.

Virology. 2010 Apr 25;400(1):145-55. doi: 10.1016/j.virol.2010.01.037. Epub 2010 Feb 21.

7.

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24. doi: 10.1089/aid.2009.0132.

8.

Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP.

PLoS Pathog. 2009 Aug;5(8):e1000548. doi: 10.1371/journal.ppat.1000548. Epub 2009 Aug 14.

9.

The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex.

Yao XJ, VĂ©lez Ruiz G, Whorton MR, Rasmussen SG, DeVree BT, Deupi X, Sunahara RK, Kobilka B.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9501-6. doi: 10.1073/pnas.0811437106. Epub 2009 May 22.

10.

Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5318-23. doi: 10.1073/pnas.0811713106. Epub 2009 Mar 16.

11.

The apparent cooperativity of some GPCRs does not necessarily imply dimerization.

Chabre M, Deterre P, Antonny B.

Trends Pharmacol Sci. 2009 Apr;30(4):182-7. doi: 10.1016/j.tips.2009.01.003. Epub 2009 Mar 5. Review.

PMID:
19269046
12.

Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.

Nolan KM, Del Prete GQ, Jordan AP, Haggarty B, Romano J, Leslie GJ, Hoxie JA.

J Virol. 2009 Apr;83(8):3798-809. doi: 10.1128/JVI.01751-08. Epub 2009 Feb 4.

13.

Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.

Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman RB, Hackney LA, Takaoka Y, Mitsuya H.

J Mol Biol. 2008 Sep 12;381(4):956-74. doi: 10.1016/j.jmb.2008.06.041. Epub 2008 Jun 20.

14.

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.

Pugach P, Ketas TJ, Michael E, Moore JP.

Virology. 2008 Aug 1;377(2):401-7. doi: 10.1016/j.virol.2008.04.032. Epub 2008 Jun 2.

15.

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR.

J Virol. 2008 Aug;82(16):8210-4. doi: 10.1128/JVI.00444-08. Epub 2008 May 21.

16.

High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation.

Altenbach C, Kusnetzow AK, Ernst OP, Hofmann KP, Hubbell WL.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7439-44. doi: 10.1073/pnas.0802515105. Epub 2008 May 19.

17.

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, Ralston R, Strizki J, Howe JA.

Virology. 2008 Apr 10;373(2):387-99. doi: 10.1016/j.virol.2007.12.009. Epub 2008 Jan 10.

18.

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.

Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M.

Mol Pharmacol. 2008 Mar;73(3):789-800. Epub 2007 Dec 20.

19.

Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD.

Science. 2007 Sep 28;317(5846):1930-4.

20.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk